# The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

> **NCT00146289** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 138 (—)

## Conditions studied

- Obesity
- Insulin Resistance

## Interventions

- **DRUG:** MICARDIS® (telmisartan)

## Key facts

- **NCT ID:** NCT00146289
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2005-10
- **Final completion:** —
- **Target enrollment:** 138 (—)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00146289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00146289, "The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00146289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*